Clinical Trials Logo

Clinical Trial Summary

In the underlying study, a genetically modified P. berghei parasite is used. P. berghei is one of the four Plasmodium species that causes malaria in rodents. The hypothesis is that immunization of humans with P. berghei will induce a cross-species immune response without the risk of a breakthrough infection. To further increase the potential for protective efficacy, the P. falciparum circumsporozoite (CS)- protein gene has been integrated in the P. berghei parasite, generating a genetically modified P. berghei parasite, abbreviated as Pb(PfCS@UIS4).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03138096
Study type Interventional
Source Radboud University
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date May 29, 2017
Completion date July 2018

See also
  Status Clinical Trial Phase
Completed NCT01935882 - Low Dose Primaquine for Clearance of Gametocytes Phase 2/Phase 3
Completed NCT01775592 - Plasmodium Falciparum Artemisinin Resistance Vietnam Phase 4
Completed NCT01728701 - Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis Phase 1
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Completed NCT02895568 - Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers
Recruiting NCT03384498 - Malaria Genetic Surveillance N/A
Completed NCT02259426 - Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission Phase 3
Completed NCT01465048 - Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe N/A
Active, not recruiting NCT00392015 - NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1 Phase 1/Phase 2
Completed NCT00295581 - PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria Phase 1
Recruiting NCT01322581 - A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali
Completed NCT02418962 - Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults Phase 1
Not yet recruiting NCT03452475 - Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children Phase 3
Completed NCT01160562 - Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity
Completed NCT03132402 - ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. Falciparum
Recruiting NCT03172221 - Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women N/A
Not yet recruiting NCT03219281 - Prevalence Survey of Antimalarial Drug Resistance Markers at Sites in India N/A
Completed NCT02090036 - Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes Phase 4
Completed NCT00197054 - A Study to Evaluate Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya. Phase 2
Completed NCT01930331 - Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Phase 4